The recommended dosage of Revlimid will depend on how well your kidneys are functioning, the reason you are taking this medication, and other factors. This prescription drug comes as a capsule that is taken once a day. If you develop serious side effects, you may need to stop treatment temporarily. After the problem improves, you may restart the medication, usually at a lower dosage.
An Introduction to Dosing With RevlimidThe dose of Revlimid® (lenalidomide) your healthcare provider recommends will vary, depending on a number of factors, including:
- The reason you are taking the medication
- How you respond to the medication
- How well your kidneys work.
As is always the case, do not adjust your dosage unless your healthcare provider specifically tells you to do so.
Recommended Revlimid Dosage for Multiple MyelomaThe usual recommended dose of Revlimid for the treatment of multiple myeloma is 25 mg a day for 21 days, followed by 7 days of no medication. This 28-day cycle is then repeated. People with kidney disease will normally be started on a lower dosage.
Revlimid is given in combination with dexamethasone when used to treat multiple myeloma. The usual dose of dexamethasone is 40 mg daily on days 1 through 4, 9 through 12, and 17 through 20 of the first 4 cycles, followed by 40 mg daily given only on days 1 through 4 of each subsequent 28-day cycle.
People who experience potentially dangerous Revlimid side effects, such as low blood cell counts, may need to temporarily stop taking this drug. The medication may be restarted, usually at a lower dose, when the side effects improve.
Recommended Revlimid Dosage for Myelodysplastic SyndromesThe usual recommended dosage for the treatment of myelodysplastic syndromes is 10 mg once a day. People with kidney disease are usually started on a lower amount.
People who experience potentially dangerous Revlimid side effects, such as low blood cell counts, may need to temporarily stop treatment. The medicine may be restarted when the side effects improve, usually at a lower dose.